Apalutamide for the treatment of prostate cancer

References

• International Agency for Research on Cancer. Prostate cancer: estimated incidence, mortality, and prevalence worldwide. GLOBOCAN web site. [Internet]. [ Cited June 29, 2017]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• SEER cancer stat facts: prostate cancer. National Cancer Institute, Bethesda, MD [Internet]. [ Cited July 6, 2017]. Available from: https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440.
   PubMed Web of Science ®Google Scholar
• Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55(3):323–327.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• James ND, De Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• Janssen Biotech Inc. Zytiga (abiraterone acetate) tablets. Prescribing information. Horsham, PA; 2018 February.
   Google Scholar
• National Comprehensive Cancer Network. Prostate cancer (Version1.2018) [Internet]. 2018 [Cited 2018 Mar 13]. Available from: https://ww.nccn.org/
   Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIOG guidelines on prostate cancer [Internet]. 2016 [updated March 2016; accessed 28 Feb 2018]]. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016-Pocket.pdf
   Google Scholar
• McKay RR, Montgomery B, Xie W, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. In: Prostate Cancer Prostatic Dis. 2017. 20 Dec [Epub ahead of print], doi: 10.1038/s41391-017-0009-6.
   Web of Science ®Google Scholar
• Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705–3715.
   PubMed Web of Science ®Google Scholar
• Graham L, Schweizer MT. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Med Oncol. 2016;33(5):44.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67(3):470–479.
   PubMed Web of Science ®Google Scholar
• Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010;53(7):2779–2796.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465-2474.
   Google Scholar
• Safety and efficacy study of enzalutamide plus leuprolide in patients with nonmetastatic prostate cancer (EMBARK) [Internet] [July 12, 2018]. Available from: https://clinicaltrials.gov/show/NCT02319837.
   Google Scholar
• A study of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC) (ARCHES) [Internet]. [July 11, 2018]. Available from: https://clinicaltrials.gov/show/NCT02677896.
   Google Scholar
• Phase III radium 223 mCRPC-PEACE III (PEACE III) [Internet]. [April 25, 2018]. Available from: https://clinicaltrials.gov/show/NCT02194842.
   Google Scholar
• Enzalutamide with or without abiraterone and prednisone in treating patients with castration-resistant metastatic prostate cancer [Internet]. [April 9, 2018]. Available from: https://clinicaltrials.gov/ct2/show/NCT01949337.
   Google Scholar
• Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975–985.
   PubMed Web of Science ®Google Scholar
• Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of BAY1841788 (ODM-201) in men with high-risk nonmetastatic castration-resistant prostate cancer (ARAMIS) [Internet]. [July 30, 2018]. Available from: https://clinicaltrials.gov/show/NCT02200614.
   Google Scholar
• ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer (ARASENS) [Internet]. [July 30, 2018]. Available from: https://clinicaltrials.gov/show/NCT02799602.
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–1503.
   PubMed Web of Science ®Google Scholar
• Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3(9):1020–1029.
   PubMed Web of Science ®Google Scholar
• Phase 1/2A study of TRC253, an androgen receptor antagonist, in metastatic castration-resistant prostate cancer patients [Internet]. [ Cited March 29, 2018]. Available from: https://clinicaltrials.gov/show/NCT02987829.
   Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–3530.
   PubMed Web of Science ®Google Scholar
• Study to assess drug-drug interaction between itraconazole or gemfibrozil and JNJ-56021927 [Internet]. [October 20, 2016]. Available from: https://clinicaltrials.gov/show/NCT02230033.
   Google Scholar
• A study to evaluate the effect of multiple doses of JNJ-56021927 on the pharmacokinetics of multiple cytochrome P450 and transporter substrates in participants with castration-resistant prostate cancer [Internet]. [July 20, 2018]. Available from: https://clinicaltrials.gov/show/NCT02592317.
   Google Scholar
• Rathkopf DE, Antonarakis ES, Shore ND, et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res. 2017;23(14):3544–3551.
   PubMed Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70(6):963–970.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–1418.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, Ryan CJ, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017;28(9):2264–2271.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Small EJ, Saad F, Chowdhury S, et al. SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 2018;36:suppl 6S; abstr 161.
   Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–164.
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897–7903.
   PubMed Web of Science ®Google Scholar
• Janssen Products L. Erleada (apalutamide) tablets. Prescribing information. Horsham, PA; 2018 February.
   Google Scholar
• U.S. Food & Drug Administration. FDA approves new treatment for a certain type of prostate cancer using a novel clinical trial endpoint [Internet]. 2018 [Cited 2018 Feb 26]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm.
   Google Scholar
• Antonarakis ES, Armstrong AJ, Dehm SM, et al. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19(3):231–241.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Chandhasin C, Osbourne E, et al. Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer. Oncologist. 2016;21(12):1427–1435.
   PubMed Web of Science ®Google Scholar
• Galletti G, Leach BI, Lam L, et al. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27.
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711.
   PubMed Web of Science ®Google Scholar
• Ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with metastatic castrate-resistant prostate cancer (IPATential150) [Internet]. [July 24, 2018]. Available from: https://clinicaltrials.gov/show/NCT03072238.
   Google Scholar
• Teo MY, O’Shaughnessy MJ, McBride SM, et al. Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nat Rev Clin Oncol. 2018;15(3):168–182.
   PubMed Web of Science ®Google Scholar
• An efficacy and safety study of apalutamide (JNJ-56021927) in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in participants with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) [Internet]. [July 27, 2018]. Available from: https://clinicaltrials.gov/show/NCT02257736.
   Google Scholar
• A study of apalutamide (JNJ-56021927, ARN-509) plus androgen deprivation therapy (ADT) versus ADT in participants with mHSPC (TITAN) [Internet]. [March 27, 2018]. Available from: https://clinicaltrials.gov/show/NCT02489318.
   Google Scholar
• An efficacy and safety study of JNJ-56021927 (Apalutamide) in high-risk prostate cancer subjects receiving primary radiation therapy: ATLAS [Internet]. [July 27, 2018]. Available from: https://clinicaltrials.gov/show/NCT02531516.
   Google Scholar